Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Advanced Therapy Medicinal Products CDMO Market, by Indication
1.4.2 LAMEA Advanced Therapy Medicinal Products CDMO Market, by Product
1.4.3 LAMEA Advanced Therapy Medicinal Products CDMO Market, by Phase
1.4.4 LAMEA Advanced Therapy Medicinal Products CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2019, Jan – 2022, Aug) Leading Players
Chapter 4. LAMEA Advanced Therapy Medicinal Products CDMO Market by Indication
4.1 LAMEA Oncology Market by Country
4.2 LAMEA Cardiology Market by Country
4.3 LAMEA Central Nervous System & Musculoskeletal Market by Country
4.4 LAMEA Infectious Disease Market by Country
4.5 LAMEA Dermatology Market by Country
4.6 LAMEA Endocrine, Metabolic, Genetic Market by Country
4.7 LAMEA Immunology & Inflammation Market by Country
4.8 LAMEA Ophthalmology Market by Country
4.9 LAMEA Hematology Market by Country
4.1 LAMEA Gastroenterology Market by Country
4.11 LAMEA Others Market by Country
Chapter 5. LAMEA Advanced Therapy Medicinal Products CDMO Market by Product
5.1 LAMEA Gene Therapy Market by Country
5.2 LAMEA Cell Therapy Market by Country
5.3 LAMEA Tissue Engineered & Others Market by Country
Chapter 6. LAMEA Advanced Therapy Medicinal Products CDMO Market by Phase
6.1 LAMEA Phase I Market by Country
6.2 LAMEA Phase II Market by Country
6.3 LAMEA Phase III Market by Country
6.4 LAMEA Phase IV Market by Country
Chapter 7. LAMEA Advanced Therapy Medicinal Products CDMO Market by Country
7.1 Brazil Advanced Therapy Medicinal Products CDMO Market
7.1.1 Brazil Advanced Therapy Medicinal Products CDMO Market by Indication
7.1.2 Brazil Advanced Therapy Medicinal Products CDMO Market by Product
7.1.3 Brazil Advanced Therapy Medicinal Products CDMO Market by Phase
7.2 Argentina Advanced Therapy Medicinal Products CDMO Market
7.2.1 Argentina Advanced Therapy Medicinal Products CDMO Market by Indication
7.2.2 Argentina Advanced Therapy Medicinal Products CDMO Market by Product
7.2.3 Argentina Advanced Therapy Medicinal Products CDMO Market by Phase
7.3 UAE Advanced Therapy Medicinal Products CDMO Market
7.3.1 UAE Advanced Therapy Medicinal Products CDMO Market by Indication
7.3.2 UAE Advanced Therapy Medicinal Products CDMO Market by Product
7.3.3 UAE Advanced Therapy Medicinal Products CDMO Market by Phase
7.4 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market
7.4.1 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Indication
7.4.2 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Product
7.4.3 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Phase
7.5 South Africa Advanced Therapy Medicinal Products CDMO Market
7.5.1 South Africa Advanced Therapy Medicinal Products CDMO Market by Indication
7.5.2 South Africa Advanced Therapy Medicinal Products CDMO Market by Product
7.5.3 South Africa Advanced Therapy Medicinal Products CDMO Market by Phase
7.6 Nigeria Advanced Therapy Medicinal Products CDMO Market
7.6.1 Nigeria Advanced Therapy Medicinal Products CDMO Market by Indication
7.6.2 Nigeria Advanced Therapy Medicinal Products CDMO Market by Product
7.6.3 Nigeria Advanced Therapy Medicinal Products CDMO Market by Phase
7.7 Rest of LAMEA Advanced Therapy Medicinal Products CDMO Market
7.7.1 Rest of LAMEA Advanced Therapy Medicinal Products CDMO Market by Indication
7.7.2 Rest of LAMEA Advanced Therapy Medicinal Products CDMO Market by Product
7.7.3 Rest of LAMEA Advanced Therapy Medicinal Products CDMO Market by Phase
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc. (Patheon, Inc.)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 AGC Biologics, Inc. (AGC, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.2.5.3 Geographical Expansions:
8.3 Catalent, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.4 Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental Analysis
8.5.4 Recent strategies and developments:
8.5.4.1 Product Launches and Product Expansions:
8.5.4.2 Acquisition and Mergers:
8.5.4.3 Partnerships, Collaborations, and Agreements:
8.6 Lonza Group AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Geographical Expansions:
8.7 Celonic AG (JRS PHARMA GmbH & Co. KG)
8.7.1 Company Overview
8.8 Bio Elpida (Polyplus-transfection SA.)
8.8.1 Company Overview
8.9 Rentschler Biopharma SE
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Partnerships, Collaborations, and Agreements:
8.9.2.2 Acquisition and Mergers:
Unique Offerings 